Serum TGF-β as a predictive biomarker for severe disease and fatality of COVID-19.
COVID-19
SARS-CoV-2
TGF-β
acute respiratory distress syndrome
biomarker
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
28
06
2023
received:
14
02
2023
accepted:
29
06
2023
medline:
23
10
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
For targeted intervention in coronavirus disease 2019 (COVID-19), there is a high medical need for biomarkers that predict disease progression and severity in the first days after symptom onset. This study assessed the utility of early transforming growth factor β (TGF-β) serum levels in COVID-19 patients to predict disease severity, fatality, and response to dexamethasone therapy. Patients with severe COVID-19 had significantly higher TGF-β levels (416 pg/mL) as compared to patients with mild (165 pg/mL, p < 0.0001) or moderate COVID-19 (241 pg/mL; p < 0.0001). Receiver operating characteristics area under the curve values were 0.92 (95% confidence interval [CI] 0.85-0.99, cut-off: 255 pg/mL) for mild versus severe COVID-19, and 0.83 (95% CI 0.65-1.0, cut-off: 202 pg/mL) for moderate versus severe COVID-19. Patients who died of severe COVID-19 had significantly higher TGF-β levels (453 pg/mL) as compared to convalescent patients (344 pg/mL), and TGF-β levels predicted fatality (area under the curve: 0.75, 95% CI 0.53-0.96). TGF-β was significantly reduced in severely ill patients treated with dexamethasone (301 pg/mL) as compared to untreated patients (416 pg/mL; p < 0.05). Early TGF-β serum levels in COVID-19 patients predict, with high accuracy, disease severity, and fatality. In addition, TGF-β serves as a specific biomarker to assess response to dexamethasone treatment.
Identifiants
pubmed: 37386908
doi: 10.1002/eji.202350433
doi:
Substances chimiques
Biomarkers
0
Dexamethasone
7S5I7G3JQL
Transforming Growth Factor beta
0
TGFB1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2350433Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
https://covid19.who.int/
Wang, D., Yin, Y., Hu, C., Liu, X., Zhang, X., Zhou, S., Jian, M. et al., Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care 2020. 24: 188.
Murakami, N., Hayden, R., Hills, T., Al-Samkari, H., Casey, J., Del Sorbo, L., Lawler, P. R. et al., Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 2022. 19: 38-52.
Robinson, P. C., Liew, D. F. L., Tanner, H. L., Grainger, J. R., Dwek, R. A., Reisler, R. B., Steinman, L. et al., COVID-19 therapeutics: challenges and directions for the future. Proc. Natl. Acad. Sci. U S A 2022. 119: e2119893119.
Subramanian, A., Nirantharakumar, K., Hughes, S., Myles, P., Williams, T., Gokhale, K. M., Taverner, T. et al., Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022. 28: 1706-1714.
Witkowski, M., Tizian, C., Ferreira-Gomes, M., Niemeyer, D., Jones, T. C., Heinrich, F., Frischbutter, S. et al., Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature 2021. 600: 295-301.
Ferreira-Gomes, M., Kruglov, A., Durek, P., Heinrich, F., Tizian, C., Heinz, G. A., Pascual-Reguant, A. et al., SARS-CoV-2 in severe COVID-19 induces a TGF-beta-dominated chronic immune response that does not target itself. Nat. Commun. 2021. 12: 1961.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection, A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020. 20: e192-e197.
Lamontagne, F., Agarwal, A., Rochwerg, B., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L. et al., A living WHO guideline on drugs for covid-19. BMJ 2020. 370: m3379.
Youden, W. J., Index for rating diagnostic tests. Cancer 1950. 3: 32-35.
Lopez-Raton, M., Cadarso-Suarez, C., Rodriguez-Alvarez, M. X. and Gude-Sampedro, F., OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. J. Stat. Softw. 2014. 61: 1-36.
Jones, T. C., Biele, G., Muhlemann, B., Veith, T., Schneider, J., Beheim-Schwarzbach, J., Bleicker, T. et al., Estimating infectiousness throughout SARS-CoV-2 infection course. Science 2021. 373: eabi5273.
Hakki, S., Zhou, J., Jonnerby, J., Singanayagam, A., Barnett, J. L., Madon, K. J., Koycheva, A. et al., Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. Lancet Respir. Med. 2022. 10: 1061-1073.
Chung, E., Ojiaku, C. A., Cao, G., Parikh, V., Deeney, B., Xu, S., Wang, S. et al., Dexamethasone rescues TGF-beta1-mediated beta2-adrenergic receptor dysfunction and attenuates phosphodiesterase 4D expression in human airway smooth muscle cells. Respir. Res. 2020. 21: 256.
Jang, Y. H., Shin, H. S., Sun Choi, H, Ryu, E S., Jin Kim, M, Ki Min et al., Effects of dexamethasone on the TGF-beta1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells. Lab. Invest. 2013. 93: 194-206.
Matz, M., Fabritius, K., Lorkowski, C., Durr, M., Gaedeke, J., Durek, P., Grun, J. R. et al., Identification of T cell-mediated vascular rejection after kidney transplantation by the combined measurement of 5 specific MicroRNAs in blood. Transplantation 2016. 100: 898-907.
Group, R. C., Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L. et al., Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021. 384: 693-704.
Richards, F., Kodjamanova, P., Chen, X., Li, N., Atanasov, P., Bennetts, L., Patterson, B. J. et al., Economic burden of COVID-19: a systematic review. Clinicoecon. Outcomes Res. 2022. 14: 293-307.
Biering, S. B., de Sousa, F. T. G., Tjang, L. V., Pahmeier, F., Ruan, R., Blanc, S. F., Patel, T. S. et al., SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-beta signaling. Biorxiv 2021. 13: 7630.
Wang, W., Chen, J., Hu, D., Pan, P., Liang, L., Wu, W., Tang, Y. et al., SARS-CoV-2 N protein induces acute kidney injury via Smad3-dependent G1 cell cycle arrest mechanism. Adv. Sci. (Weinh) 2022. 9: e2103248.
Zhao, X., Nicholls, J. M. and Chen, Y. G., Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J. Biol. Chem. 2008. 283: 3272-3280.
Stukalov, A., Girault, V., Grass, V., Karayel, O., Bergant, V., Urban, C., Haas, D. A. et al., Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 2021. 594: 246-252.
Hand, T. W. and Reboldi, A., Production and function of immunoglobulin A. Annu. Rev. Immunol. 2021. 39: 695-718.
Hu, Y., Hudson, W. H., Kissick, H. T., Medina, C. B., Baptista, A. P., Ma, C., Liao, W. et al., TGF-beta regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection. J. Exp. Med. 2022. 219: e20211574.
Moreau, J. M., Velegraki, M., Bolyard, C., Rosenblum, M. D. and Li, Z., Transforming growth factor-beta1 in regulatory T cell biology. Sci. Immunol. 2022. 7: eabi4613.
Xu, S. W., Ilyas, I. and Weng, J. P., Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2022. 44: 695-709.
Iempridee, T., Das, S., Xu, I. and Mertz, J. E., Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene. J. Virol. 2011. 85: 7836-7848.
Beller, A., Kruglov, A., Durek, P., von Goetze, V., Werner, K., Heinz, G. A., Ninnemann, J. et al., Specific microbiota enhances intestinal IgA levels by inducing TGF-beta in T follicular helper cells of Peyer's patches in mice. Eur. J. Immunol. 2020. 50: 783-794.
Dabiri, G., Campaner, A., Morgan, J. R. and Van De Water, L., A TGF-beta1-dependent autocrine loop regulates the structure of focal adhesions in hypertrophic scar fibroblasts. J. Invest. Dermatol. 2006. 126: 963-970.
Chen, C., Wang, X. F. and Sun, L., Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J. Biol. Chem. 1997. 272: 12862-12867.
Watanabe, T., Tajima, H., Hironori, H., Nakagawara, H., Ohnishi, I., Takamura, H., Ninomiya, I. et al., Sodium valproate blocks the transforming growth factor (TGF)-beta1 autocrine loop and attenuates the TGF-beta1-induced collagen synthesis in a human hepatic stellate cell line. Int. J. Mol. Med. 2011. 28: 919-925.
Woodruff, M. C., Ramonell, R. P., Haddad, N. S., Anam, F. A., Rudolph, M. E., Walker, T. A., Truong, A. D. et al., Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 2022. 611: 139-147.
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M. et al., Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020. 146: 128-136 e124.
Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., Li, B. et al., Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol. 2020. 127: 104370.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L. et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. 395: 497-506.
Hirano, T. and Murakami, M., COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020. 52: 731-733.
Wilson, J. G., Simpson, L. J., Ferreira, A. M., Rustagi, A., Roque, J., Asuni, A., Ranganath, T. et al., Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight 2020. 5: e140289.
dupont, N. C., Wang, K., Wadhwa, P. D., Culhane, J. F. and Nelson, E. L., Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J. Reprod. Immunol. 2005. 66: 175-191.
Chowdhury, F., Williams, A. and Johnson, P., Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods 2009. 340: 55-64.
Ghazavi, A., Ganji, A., Keshavarzian, N., Rabiemajd, S. and Mosayebi, G., Cytokine profile and disease severity in patients with COVID-19. Cytokine 2021. 137: 155323.
Carvacho, I. and Piesche, M., RGD-binding integrins and TGF-beta in SARS-CoV-2 infections-novel targets to treat COVID-19 patients? Clin. Transl. Immunology 2021. 10: e1240.